Tesamorelin and CJC-1295/ipamorelin both raise growth hormone, but they are not interchangeable. Tesamorelin is an FDA-approved drug with randomized trial data for one specific condition. CJC-1295/ipamorelin is a compounded combination with a large following and very little published human trial evidence. Neither is an approved weight loss treatment for the general adult population.
This guide compares how each works, what the evidence shows, what the safety and sourcing questions are, and when a different path, such as doctor-led GLP-1 care, is more likely to match your goal.
TL;DR
- Tesamorelin is a growth hormone-releasing hormone (GHRH) analog approved by the FDA to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. It is not approved for general weight loss.
- CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin receptor agonist) are used together as a compounded blend. They are not FDA-approved products, and published human randomized trials are lacking.
- Tesamorelin has the stronger evidence, but in a narrow population. The blend is cheaper and more flexible, with weaker proof.
- Visceral fat returns after tesamorelin is stopped, so any benefit depends on continued treatment.
- If your goal is weight loss, GLP-1 medication has a much clearer role. A clinician should decide what fits your health history.
Table of Contents
- How the two options work
- Side-by-side comparison
- What the evidence says
- Can you take them together?
- Safety and sourcing: the part most comparisons skip
- Which one fits which goal?
- Our perspective
- Where Dayla Health fits
- Questions people ask
- Sources
How the two options work
Both approaches target the same hormone axis. The pituitary gland releases growth hormone (GH) in pulses, and GH then prompts the liver to produce IGF-1. The difference is which signal each compound uses to prompt the release.
Tesamorelin: a single GHRH analog
Tesamorelin is a synthetic analog of growth hormone-releasing hormone. PubMed's drug review describes it as stimulating the synthesis and release of your own growth hormone. It is sold as a branded injectable, Egrifta, given under the skin once a day. The FDA label lists a recommended dose of 2 mg daily for the original formulation.
In March 2025 the FDA also approved a concentrated version, Egrifta WR. Clinical Advisor reported that it was supported by studies showing bioequivalence to the 2 mg dose. The indication did not change.
CJC-1295 and ipamorelin: two signals in one blend
CJC-1295 is also a GHRH analog. Ipamorelin works on a different receptor, the ghrelin receptor, as a growth hormone secretagogue. The idea behind the blend is that two different signals together produce a larger, still pulsatile GH release than either alone. Compounders often combine them in one vial, and the product is usually the version without a drug affinity complex, given more than once a week or nightly depending on the protocol.
If you want the ipamorelin side explained in more depth, see our guide to what ipamorelin is and how it is used. For dosing schedules and safety practices around the blend, read the CJC-1295/ipamorelin cycle guide.
Side-by-side comparison
| Factor | Tesamorelin | CJC-1295/ipamorelin |
|---|---|---|
| Type | Single GHRH analog | GHRH analog plus ghrelin receptor agonist |
| FDA status | Approved (Egrifta, Egrifta WR) | Not an approved product; compounded |
| Approved use | Excess abdominal fat in HIV-infected adults with lipodystrophy | None |
| Human trial evidence | Randomized placebo-controlled trials in the approved population | Published human randomized trials are lacking |
| Main goal people seek it for | Visceral fat reduction | Recovery, sleep, body composition, anti-aging |
| Manufacturing oversight | FDA-approved manufacturing standards | Depends on the compounding source |
| Typical cost | Generally higher | Generally lower |
The cost row reflects what clinics and reviewers commonly report, not a figure we can source to a single price. Ask any provider for the exact cash price before you start.
What the evidence says
Tesamorelin: strong data, narrow population
The pivotal trials enrolled HIV-infected patients on antiretroviral therapy who had excess abdominal fat. In a randomized placebo-controlled trial with a safety extension, the researchers tested whether tesamorelin selectively reduced visceral fat in that group. An earlier 26-week study reported a significant decrease in visceral adipose tissue and improved lipids. The FDA label data summarized in our research show roughly a 15% to 18% reduction in visceral fat over 26 to 52 weeks.
Two points matter for you as a reader.
- The label is narrow. The FDA label limits use to HIV-infected adults with lipodystrophy and notes that long-term cardiovascular safety has not been established. It is not a weight loss drug, and studies show it is weight-neutral.
- The effect does not last without the drug. Trial data show visceral fat tends to come back after treatment stops. Tesamorelin manages a condition. It does not cure fat storage.
So when an online article says tesamorelin "targets belly fat" in healthy adults, the proof it cites comes from a different group of people.
CJC-1295/ipamorelin: popular, thinly studied
The blend has a strong reputation in wellness circles. The evidence is another matter. A Scientific American review quotes urologist Alexander Pastuszak saying there is a profound lack of large human trials of these compounds in healthy adults for weight loss, body composition or longevity. Geriatrician Anne Cappola adds that current data do not definitively show improvements in physical function, mobility or strength, which matter more for long-term health than a change in a body fat measurement.
Raising GH or IGF-1 on a lab test is not the same as a better outcome for you. That gap applies to both options, and it is wider for the blend.
Can you take them together?
People often ask whether tesamorelin and CJC-1295 can be stacked. Both are GHRH analogs, so they act on the same receptor. We are not aware of human trial data supporting the combination, and stacking two drugs of the same class raises the question of what you are adding. This is a decision for a licensed clinician who knows your history, not something to improvise from a forum post. If you have a history of cancer, diabetes, or pituitary problems, say so before any GH-axis product is considered.
Safety and sourcing: the part most comparisons skip
The two options differ most in where they come from.
Tesamorelin is made to FDA-approved manufacturing standards. Compounded peptides are not held to the same approval process. FDA inspections of compounders have found problems, including a 2022 inspection report for a Texas facility that describes a non-pharmaceutical grade component used in a CJC-1295/ipamorelin solution and an inadequate test. That is one facility, not every compounder, but it shows why sourcing matters for something you inject.
The gray market is worse. According to the Scientific American review, independent testing found that 40% to 70% of gray-market peptide samples failed basic purity and identity criteria, and about 15% had detectable endotoxins. "Research use only" vials are not medication.
The regulatory ground has also shifted. In September 2024 the FDA removed CJC-1295 and ipamorelin acetate from Category 2 of its interim 503A bulks list after the nominations were withdrawn, and said it would review these and other peptides for possible inclusion in the 503A bulks regulation. Rules like this can change again, so check the current FDA position before you assume anything about availability.
A practical checklist before you use any injectable peptide:
- Get a prescription from a licensed clinician after a real evaluation.
- Ask which pharmacy compounds it and whether it is a licensed U.S. pharmacy.
- Ask for the lot, the beyond-use date and storage instructions.
- Never buy vials labeled for research and inject them.
- Report any injection-site reaction, swelling, numbness or fluid retention to your prescriber.
Handling is part of safety too. If you use an approved tesamorelin product, follow the label and your pharmacist's mixing instructions. For readers who want a step-by-step explainer on how reconstitution works, a tesamorelin reconstitution reference is available, though it is in Dutch and does not replace instructions from your prescriber or pharmacist.
Which one fits which goal?
If your goal is visceral fat and you have HIV-associated lipodystrophy
Tesamorelin is the evidence-backed option, and it is the one with an FDA indication. Work with your HIV care team. They will weigh cardiovascular risk and decide whether to continue, since the benefit fades after you stop.
If your goal is recovery, sleep or general "optimization"
This is where CJC-1295/ipamorelin is most often used. Be realistic: the claims here outrun the trials. If you go ahead, do it under clinician oversight, with a licensed pharmacy source and a plan to measure something that matters to you, such as sleep quality or training performance, not just a lab number.
If your goal is weight loss
Neither is the right starting point. Tesamorelin is weight-neutral in studies. The blend lacks human weight loss trials. For weight loss, the better-studied route is GLP-1 medication with nutrition support. Our weight loss peptides comparison guide lays out how peptide options differ, and our visceral fat reduction guide covers belly fat specifically. If you are worried about losing lean mass while you lose weight, see peptides for muscle preservation.
Our perspective
We see the same pattern in the questions patients bring us. They have read that a peptide "melts belly fat" and want to know which one to pick. We start one step earlier: what outcome do you want, and what does the evidence say about reaching it?
Our view is plain. Tesamorelin is a legitimate medicine for the population it was studied in. The CJC-1295/ipamorelin blend is a popular compounded option with limited human data, and it belongs under doctor-led care, not in a gym bag. We would rather tell you that than sell you a promise.
For weight loss, we focus on personalized GLP-1 care: a clinician evaluation, medication, dietitian visits and care coaching in one plan. For peptides, we apply the same standard. A clinician reviews your history first, and approval is never automatic. Our growth hormone peptides page explains how that process works.
— Flexible
Where Dayla Health fits
If you came here hoping to lose weight, a doctor-led GLP-1 plan is the path we recommend exploring first. You complete an online intake, a clinician reviews it, and if you are approved your medication ships to you anywhere in the U.S. No insurance is needed. Published plan pricing on our site is:
- GLP-1 Injection: from $179 per month
- GLP-1 Microdose: from $159 per month
- Oral GLP, liposomal: from $149 per month
- dayla GLP-1 program: $299 per month
Plans include clinical oversight, free dietitian visits and care coaching, with flexible cancellation. See the weight loss collection to compare options. Whether you qualify is a clinician's decision.
Questions people ask
What is better, CJC-1295/ipamorelin or tesamorelin?
It depends on the goal. Tesamorelin has FDA approval and randomized trial data, but only for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. CJC-1295/ipamorelin has wider use and lower cost, but published human trials are lacking. For general weight loss, neither is the best-supported option.
Is tesamorelin stronger than ipamorelin?
They act differently, so "stronger" is hard to measure. Tesamorelin is a GHRH analog with trial-proven effects on visceral fat in its approved group, including increases in IGF-1. Ipamorelin acts on the ghrelin receptor and lacks equivalent trials. Potency on a lab test does not equal a better result for you.
Does tesamorelin help with general weight loss?
No. The FDA label does not indicate it for weight loss management, and studies show a weight-neutral effect. Trials also show visceral fat returns after treatment stops.
Are compounded peptides safe?
Safety depends on the source. Compounded drugs do not go through FDA approval, and FDA inspections have documented sterility and component problems at some facilities. Use only a prescription filled by a licensed U.S. pharmacy, and avoid research-grade vials sold online.
Sources
- EGRIFTA (tesamorelin) FDA prescribing information
- Tesamorelin: a review of its use in HIV-associated lipodystrophy (PubMed)
- Randomized placebo-controlled trial of tesamorelin with a safety extension (PubMed)
- Long-term safety and effects of tesamorelin in HIV patients (PubMed)
- New formulation of tesamorelin approved, Clinical Advisor
- Growth hormone peptides and the science, Scientific American
- FDA Form 483, Richardson, TX compounding facility
- FDA peptide bulk substances removed from Category 2, Lexology